
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an experimental oral therapy targeting acute …

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to their supply chains to increase …

In the decade to 2025, AI use in vaccine development has increased markedly but is the boom in research translating …

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of Excellence in Ontario, Canada after …

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) …

ELRIG, a non-profit volunteer-led organisation dedicated to the drug discovery community, has appointed Del Trezise as chair of the board. …

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its facility …

CluePoints has appointed Usama Dar as its new chief product and technology officer, effective 1 April 2025. This follows Darโs …

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat …

Medidata has announced the launch of its Medidata Site Insights Program โ a collection of initiatives intended to foster more …

Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug …

Domestic and international markets in Asia surging as CPHI & PMEC China welcomes a staggering 93,000 attendees 08 August, 2024, …

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug Administration (FDA) for its artificial …

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeuticsโ Investigational New Drug (IND) application …

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …